Central micrOperimetry and Radial OCT Evaluation in Geographic Atrophy (CORE-GA): a Prospective Pilot Study (CORE-GA)

April 22, 2026 updated by: University of California, San Francisco
This study is being conducted to assess two imaging methods-central microperimetry and radial OCT (Optical Coherence Tomography)-in patients with Geographic Atrophy (GA) or those who are at risk of developing this condition. The study team is trying to determine whether these methods can provide more accurate measurements of GA progression toward the foveal center, the central part of the retina responsible for your sharpest, most detailed vision.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

80

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • United States
    • California
      • San Francisco, California, United States, 94143
        • Recruiting
        • University of California, San Francisco
        • Contact:
        • Principal Investigator:
          • Jay M Stewart, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients with age-related macular degeneration.

Description

Inclusion Criteria:

  • Subjects must be 55+ years of age Subjects in the "Intermediate AMD Observation Arm" must have intermediate age-related macular degeneration in one eye

Subjects in the "GA Observation Arm", "GA Continuing Treatment Arm", and "GA Treatment Arm" must have non-central GA (defined as GA has not involved the center point of the fovea) and at least 1% GA in the central 1 mm zone.

Exclusion Criteria:

  • Subjects with central involvement of GA. Central involvement is defined as geographic atrophy involving the foveal center point.

Subjects with a baseline size of GA > 17.5mm2 (7.0 Macular Photocoagulation Study Disc Areas).

Subjects who are: pregnant women, adults who cannot consent for themselves, and those who use alcohol in excess. Excess alcohol use is defined by binge drinking (pattern of drinking that brings blood alcohol concentration levels to 0.08 g/dL) on 5 or more days in the past month.

Evidence of retinal atrophy due to causes other than atrophic AMD. Subjects who have had anti-VEGF injections or active choroidal neovascularization in the study eye during the last 12 months Current evidence or history of ocular disorders in the study eye that in the opinion of the investigator confounds study outcome measures, including (but not limited to):

  1. Non-proliferative diabetic retinopathy involving 10 or more hemorrhages or microaneurysms, or active proliferative diabetic retinopathy
  2. Branch or central retinal vein or artery occlusion
  3. Macular hole
  4. Pathologic myopia
  5. Uveitis
  6. Pseudovitelliform maculopathy
  7. Intraoperative surgery within the last 90 days prior to study eye enrollment

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Non-central geographic atrophy not being treated
Patients with age-related macular degeneration who have geographic atrophy that does not involve the fovea.
Diagnostic test: Optical coherence tomography
High-resolution imaging method used to evaluate the structure of the retina
Other Names:
  • OCT
Diagnostic test: Microperimetry
A functional test that maps retinal sensitivity by measuring how well you can detect lights in different areas of your vision.
Intermediate age-related macular degeneration
Patients with intermediate age-related macular degeneration
Diagnostic test: Optical coherence tomography
High-resolution imaging method used to evaluate the structure of the retina
Other Names:
  • OCT
Diagnostic test: Microperimetry
A functional test that maps retinal sensitivity by measuring how well you can detect lights in different areas of your vision.
Non-central geographic atrophy currently being treated
Patients with non-central geographic atrophy from age-related macular degeneration who are currently receiving treatment for this condition.
Diagnostic test: Optical coherence tomography
High-resolution imaging method used to evaluate the structure of the retina
Other Names:
  • OCT
Diagnostic test: Microperimetry
A functional test that maps retinal sensitivity by measuring how well you can detect lights in different areas of your vision.
Non-central geographic atrophy initiating treatment
Patients with non-central geographic atrophy from age-related macular degeneration who will be starting to receive treatment for this condition.
Diagnostic test: Optical coherence tomography
High-resolution imaging method used to evaluate the structure of the retina
Other Names:
  • OCT
Diagnostic test: Microperimetry
A functional test that maps retinal sensitivity by measuring how well you can detect lights in different areas of your vision.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Geographic atrophy progression rate
Time Frame: 1 year
Quantify the progression rate of geographic atrophy toward the foveal center over time
1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Longitudinal progression of macular sensitivity over time
Time Frame: 1 year
Measure macular sensitivity over time.
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of California, San Francisco

Investigators

  • Principal Investigator: Jay Stewart, MD, University of California, San Francisco

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 11, 2025

Primary Completion (Estimated)

June 11, 2027

Study Completion (Estimated)

June 11, 2027

Study Registration Dates

First Submitted

April 22, 2026

First Submitted That Met QC Criteria

April 22, 2026

First Posted (Actual)

April 29, 2026

Study Record Updates

Last Update Posted (Actual)

April 29, 2026

Last Update Submitted That Met QC Criteria

April 22, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 25-43635

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Age-Related Macular Degeneration

Clinical Trials on Optical coherence tomography

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Qatar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe